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Abstract: Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are
progressive and fatal neurodegenerative disorders showing mislocalization and cytosolic accumulation
of TDP-43 inclusions in the central nervous system. The decrease in the efficiency of the clearance
systems in aging, as well as the presence of genetic mutations of proteins associated with cellular
proteostasis in the familial forms of TDP-43 proteinopathies, suggest that a failure of these protein
degradation systems is a key factor in the aetiology of TDP-43 associated disorders. Here we show
that the internalization of human pre-formed TDP-43 aggregates in the murine neuroblastoma N2a
cells promptly resulted in their ubiquitination and hyperphosphorylation by endogenous machineries,
mimicking the post-translational modifications observed in patients. Moreover, our data identify
mitochondria as the main responsible sites for the alteration of calcium homeostasis induced by
TDP-43 aggregates, which, in turn, stimulates an increase in reactive oxygen species and, finally,
caspase activation. The inhibition of TDP-43 proteostasis in the presence of selective inhibitors against
the proteasome and macroautophagy systems revealed that these two systems are both severely
involved in TDP-43 accumulation and have a strong influence on each other in neurodegenerative
disorders associated with TDP-43.
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1. Introduction
Frontotemporal lobar degeneration with ubiquitin positive inclusions (FTLD-U) and amyotrophic
lateral sclerosis (ALS) are devastating neurodegenerative diseases characterized by the mislocalization
and cytosolic accumulation of the predominately nuclear TAR DNA-binding protein 43 (TDP-43) in the
central nervous system [1,2]. FTLD-U is a cortical dementia, involving degeneration of the frontal and
temporal brain lobes and hippocampus, characterized by TDP-43 positive inclusions in the neurons [1].
By contrast, in ALS patients, the inclusions bodies of TDP-43 were mainly found to accumulate in
the upper and lower motoneurons of the brain, brainstem, and spinal cord, causing a progressive
degeneration of these cells [3]. The presence of TDP-43 neuropathology in ~97% of ALS and ~50% of
FTLD cases [4] provides a molecular link, connecting both diseases as a clinicopathological spectrum
of the TDP-43 proteinopathies [1,5,6].
A number of physiological functions are perturbed in FTLD and ALS, including impaired
protein homeostasis, RNA dysmetabolism, and reduced nucleocytoplasmic transport of mRNAs
and proteins [4,7,8]. The cytoplasmic deposition of TDP-43 occurs concomitantly with the depletion
of native TDP-43 from the nucleus [1], causing neurodegeneration in both FTLD-U and ALS by a
combination of gain-of-function (GOF) and loss-of-function (LOF) mechanisms [1,9,10]. Cytosolic
aggregates are known to be intrinsically toxic [10,11] and able to recruit nuclear TDP-43, exacerbating
their deleterious effects by contributing to the nuclear LOF [12–14]. Recent studies indicate that Ca2+
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disturbances, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction are involved in the
pathogenesis of both diseases [15–17]. Other findings also indicate that TDP-43 is capable of inducing
neurodegeneration due to the compromised function of the chromatin remodeller Chd1/CHD2, that
prevents the appropriate expression of protective genes [18].
In this scenario, it is crucial for neurons to maintain TDP-43 protein homeostasis by the
ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) [19–22]. Indeed, a
progressive decrease in the efficiency of both protein degradation systems has been reported as a major
factor contributing to FTLD-U and ALS onset in aging patients. This hypothesis is also supported
by genetic evidence, as many of the mutations associated with FTLD and ALS affect genes involved
in UPS- or ALP-mediated degradation, such as VCP, CHMP2B, OPTN, SQSTM1, TBK1, UBQLN2,
FIG4, ALS2, and C9ORF72 [23–35]. Recent studies showed that the cytosolic accumulation of TDP-43
is turned-over mainly by the UPS, with ALP contributing to its degradation when TDP-43 accumulates
as intractable aggregates [21,36]. Accordingly, we recently found that cytosolic diffuse TDP-43 can be
assembled in different species of misfolded TDP-43, ranging from soluble monomers to undegradable
macroaggregates [36].
Here we found an early ROS production and caspase-3 activation in murine neuroblastoma N2A
cells, following cytosolic transfection with preformed inclusions of human TDP-43 in the absence of
any recruitment of the nuclear TDP-43 reservoir. Moreover, our findings identify the mitochondria as
the main responsible organelle for the alteration of calcium homeostasis induced by TDP-43 aggregates.
We also showed that the UPS and ALP systems are unable to efficiently degrade at least a fraction of
the TDP-43 inclusions.
2. Results
2.1. TDP-43 Aggregates Are Ubiquitinated and Phosphorylated in Neuronal Cells
TDP-43 inclusion bodies (TDP-43 IBs) and control inclusion bodies (control IBs) were obtained
from E. coli expressing the human form of TDP-43 or an empty vector, respectively, tagged with the GST.
When TDP-43 inclusions were internalized into murine N2A neuroblastoma cells using lipofectamine,
a dense nuclear localization and a diffuse cytosolic distribution of TDP-43 (green channel) were shown
by scanning confocal microscopy using monoclonal antibodies that recognize both murine and human
isoforms of TDP-43 protein (Figure 1A,B). In contrast, just a nuclear localization of the endogenous
TDP-43 protein (red channel) was evident in cells transfected with TDP-43 IBs using antibodies specific
for the murine isoform of TDP-43 (Figure 1A,B). The cells transfected with vehicle or control IBs showed
only a nuclear TDP-43 fluorescence (Figure 1A–C). Of importance, the levels of nuclear endogenous
TDP-43 at 0 h were similar in the various conditions (Figure 1B), indicating that the transfection
procedure did not change the levels of nuclear endogenous TDP-43.
It is well established that the formation of cytoplasmic TDP-43 inclusions in neurons of FTLD-U
and motoneurons of ALS patients is accompanied by post-translational modifications of the TDP-43
protein, including ubiquitination and hyperphosphorylation [1]. Here, the images obtained by scanning
confocal microscopy showed a highly significant co-localization between exogenous cytosolic TDP-43
inclusions and ubiquitin (~85%) in N2A neuroblastoma cells, with respect to cells transfected with
control IBs (Figure 1D). The cytosolic TDP-43 inclusions also appeared phosphorylated at S409/410
sites, with a very significant co-localization with ubiquitin (~76%) (Figure 1E). By contrast, a negligible
phosphorylation and ubiquitin staining was evident in the cytoplasm of N2A cells transfected with
control IBs (Figure 1E). These data suggest that ubiquitinated and phosphorylated inclusions of the
transfected human TDP-43 are localized in the cytosol of our neuronal model, recapitulating the
post-translational modifications observed in neurodegenerative disorders.
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Figure 1. TDP-43 inclusions are ubiquitinated and phosphorylated in N2A neuroblastoma cells. (A) 
Representative confocal scanning microscope images of N2A cells transfected with vehicle, control 
IBs, and TDP-43 IBs. Red and green fluorescence indicate endogenous murine TDP-43 and total TDP-
43 (human and murine), respectively, detected with immunofluorescence. (B) Quantitative analysis 
of cytoplasmic (green bars) and nuclear (pale green bars) TDP-43-derived fluorescence 0 h after 
transfection and using antibodies specific for total (human and murine) TDP-43. The red bars refer to 
nuclear TDP-43-derived fluorescence at 0 h using antibodies specific for murine TDP-43. (C) 
Representative confocal scanning microscope images of N2A cells transfected with control IBs. Green 
and red fluorescence indicate cell membrane and endogenous murine TDP-43, respectively. (D,E) 
Representative confocal scanning microscope images showing the co-localization of cytoplasmic 
TDP-43 (D) or TDP-43 phosphorylated at Ser409/410 (E) with ubiquitin-positive aggregates in N2A 
cells transfected with control IBs or TDP-43 IBs. Green and red fluorescence indicate total TDP-43 or 
pS409/410 TDP-43 and ubiquitin, respectively. Higher magnifications of the merged images are 
shown in the boxed areas. The cytofluorograms show the cytoplasmic green fluorescence intensity (as 
pixel intensity, y axis) versus cytoplasmic red fluorescence intensity (x axis). The histograms show the 
percentage of co-localization on regions of interest (50–60 cells) using the ImageJ and JACOP plugin 
software. Error bars are S.D. *** p < 0.001 relative to cells transfected with vehicle. 
Figure 1. P-43 inclusions are ubiquitinated and phosphorylated in N2A neuroblastoma cells.
(A) Representative confocal scanning microscope images of N2A cells transfecte ith vehicle, control
IBs, and T P-43 IBs. Red and green fluorescence indicate endogenous murine TDP-43 and total
TDP-43 (human and murine), respectively, detected with immunofluorescence. (B) Quantitative
analysis of cytoplasmic (green bars) and nuclear (pale green bars) TDP-43-derived fluorescence 0 h
after transfection and using antibodies specific for total (human and murine) TDP-43. The red bars
refer to nuclear TDP-43-derived fluorescence at 0 h using antibodies specific for murine TDP-43.
(C) Representative confocal scanning microscope images of N2A cells transfected with control IBs.
Green and red fluorescence indicate cell membrane and endogenous murine TDP-43, respectively.
(D,E) Representative confocal scanning microscope images showing the co-localization of cytoplasmic
TDP-43 (D) or TDP-43 phosphorylated at Ser409/410 (E) with ubiquitin-positive aggregates in N2A
cells transfected with control IBs or TDP-43 IBs. Green and red fluorescence indicate total TDP-43
or pS409/410 TDP-43 and ubiquitin, respectively. Higher magnifications of the merged images are
shown in the boxed areas. The cytofluorograms show the cytoplasmic green fluorescence intensity (as
pixel intensity, y axis) versus cytoplasmic red fluorescence intensity (x axis). The histograms show the
percentage of co-localization on regions of interest (50–60 cells) using the ImageJ and JACOP plugin
software. Error bars are S.D. *** p < 0.001 relative to cells transfected with vehicle.
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2.2. TDP-43 Aggregates Cause Ca2+ Release from Mitochondrial Stores in Neuronal Cells
Several studies have shown abnormalities of Ca2+ homeostasis in both FTLD and ALS [7,8,37,38].
By using confocal microscopy and Fluo4 as a specific fluorescent probe, we found that transfected
TDP-43 aggregates triggered a significant and extensive increase of Ca2+ levels in the cytosol of N2A
neuroblastoma cells (Figure 2). On the contrary, cells treated with control IBs showed a cytosolic
Ca2+ content that was unchanged compared to cells treated with lipofectamine (vehicle). Then, we
investigated whether calcium dyshomeostasis was caused by a destabilization of the calcium channels
on the plasma membrane or by an imbalance of the mitochondrial calcium uptake. Thus, before TDP-43
IB internalization we incubated the cells with 5.0 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX),
which is a competitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPA-R), or with 5 µM CGP-37157 (CGP), which is an inhibitor of the mitochondrial Na+/Ca2+
exchanger, or with 10 µM cyclosporine A (CsA), which is an inhibitor of the mitochondrial permeability
transition pore (mPTP). Pre-treatment with CNQX did not prevent the alteration of Ca2+ homeostasis
induced by TDP-43 inclusions, ruling out the involvement of the AMPA receptor in intracellular Ca2+
dyshomeostasis (Figure 2). Similar results were obtained in cells treated with TDP-43 inclusions
in the presence of a cell medium without Ca2+, ruling out that the increase of intracellular Ca2+
levels had an extracellular origin. In contrast, both CGP and CsA inhibitors significantly reduced the
intracellular Ca2+ increase induced by TDP-43 inclusions, indicating the involvement of mitochondria
in the disruption of Ca2+ homeostasis (Figure 2).
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Figure 2. Analysis of intracellular Ca2+ levels. (A) Representative confocal scanning microscope 
images of N2A cells showing intracellular Ca2+ levels after transfection with vehicle, control IBs, and 
TDP-43 IBs in the absence or presence of 5 μM CNQX, 5 μM CGP, or 10 μM CsA or in medium without 
Ca2+. The green fluorescence arises from the intracellular Fluo4 probe bound to Ca2+. (B) Quantitative 
analysis of the green fluorescence arising from the Fluo4 probe. Error bars are S.D. * p < 0.05 and *** p 
< 0.001 relative to cells transfected with vehicle. 
Figure 2. Analysis of intracellu ar Ca2+ level ( ) Represen ative confocal sca ning microscope
images of N2A cells showing intracellular Ca2+ l els after transfection with vehi le, c ntrol IBs, and
TDP-43 IBs in the absence or presence of 5 µ C QX, 5 µM CGP, or 10 µM CsA or in medium without
Ca2+. The green fluorescence arises from the intracellular Fluo4 probe bound to Ca2+. (B) Quantitative
analysis of the green fluorescence arising from the Fluo4 probe. Error bars are S.D. * p < 0.05 and
*** p < 0.001 relative to cells transfected with vehicle.
Int. J. Mol. Sci. 2019, 20, 3685 5 of 14
Moreover, TDP-43 inclusions caused a significant increase in ROS production and caspase-3
activation in N2A neuronal cells (Figure 3A,B). In contrast, cells treated with lipofectamine (vehicle)
or with control IBs showed a negligible alteration of the redox and apoptotic status (Figure 3A,B).
Cells transfected with TDP-43 IBs also showed a significant decrease of cell viability with respect
to cells treated with vehicle, as assessed by the MTT test (Figure 3C). On the contrary, control IBs
showed a modest level of cytotoxicity, attributable to the aggregated protein present in the IBs. These
findings show that the cytosolic accumulation of TDP-43 inclusions stimulates the release of calcium
from the mitochondrial stores, inducing ROS production and activating the apoptotic pathway, thus
summarizing the pathological hallmarks of FTLD and ALS.
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Figure 3. Analyses of i e lular ROS production, caspase-3 activ tion, and cell viability.
(A) Represe e focal sca ning microscope images of N2A cells showing intracellular ROS
production and caspase-3 activatio after transfection with vehicle, control IBs, and TDP-43 IBs.
The green fluorescence arises from the CM-H2DCFDA probe that has reacted with ROS and from
FAM-FLICATM Caspase 3&7, respectively. (B) Quantitative analysis of the green fluorescence arising
from CM-H2DCFDA and FAM-FLICATM Caspase 3&7 probes. (C) MTT reduction of N2a cells
transfected with vehicle, control IBs and, TDP-43 IBs and analyzed after 24 h. Error bars are
S.D. *** p < 0.001 relative to cells transfected with vehicle.
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2.3. TDP-43 Aggregates Are Degraded by Proteasome and Autophagy Systems
The transfection of N2A cells with human TDP-43 inclusions allows for following the clearance of
the TDP-43 aggregates present at time 0 h, independently of the occurrence of pre-existing degradation.
We thus followed the levels of both nuclear and cytoplasmic TDP-43 in N2A cells from 0 h to 24 h after
transfection, using both antibodies specific for the total (human and murine) and only the endogenous
murine TDP-43 (Figure 4A). In cells treated with TDP-43 inclusions, the cytosolic levels of TDP-43
(green signal) decreased over time with apparent single exponential kinetics, whereas negligible levels
of cytosolic endogenous TDP-43 (red signal) were found over the 24 h time period using anti-murine
TDP-43 (Figure 4A,B). Accordingly, the nuclear levels of endogenous TDP-43 (red signal) were found
to remain constant over the explored 24 h time period after transfection with TDP-43 IBs in N2A cells
(Figure 4A,C), indicating that nuclear TDP-43 was not recruited to the cytosol by exogenous TDP-43
inclusions in our neuronal model. A plot of the cytosolic TDP-43 levels versus time showed an apparent
rate constant of clearance of 4.78(±0.59) × 10−5 s−1, a 52.11(±2.16)% of initial cytoplasmic TDP-43
aggregates that have been degraded, and a 48.67(±2.02)% of undegradable TDP-43 at the end of the
exponential phase (Figure 4B).
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To further study the efficiency of the clearance systems in N2A neurons after cytosolic insertion 
of TDP-43 inclusions, the cells were pre-treated for 8 h with either the UPS inhibitor epoxomicin or 
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Figure 4. TDP-43 clearance in N2A following the transfection with TDP-43 aggregates.
(A) Representative confocal scanning icroscope images of N2A cells that were transfected with TDP-43
IBs and a alyzed at the indicated time points after ction. Red and green fluores nce indicates
endogen us m rine TDP-43 and total TDP-43 (human and murine) detected with immunofluorescence.
(B,C) Kinetic pl ts showing cytoplasmic (B) and nuclear (C) TDP-43 derived fluorescence, detected
with Abs against total (B) and only murine (C) TDP-43 as a function of time after transfection of N2A
cells with vehicle (red), control IBs (yellow), and TDP-43 IBs (green). The line in panel (B) represents
the best fits to an exponential function. Error bars: S.D. * p < 0.05 and *** p < 0.001 relative to cells
analyzed 0 h after transfection.
To further study the efficiency of the clearance systems in N2A neurons after cytosolic insertion
of TDP-43 inclusions, the cells were pre-treated for 8 h with either the UPS inhibitor epoxomicin or
the ALP inhibitor bafilomycin and then the levels of TDP-43 were analyzed using specific antibodies
(Figure 5). When TDP-43-derived fluorescence was plotted versus time, apparent single exponential
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kinetics were observed in all cases (Figure 5A,B). The 25.75(±2.05)% value of decreased fluorescence
obtained in the presence of epoxomicin represents the fraction of aggregated cytoplasmic TDP-43 that is
degradable via the ALP (Figure 5B), a percent level significantly lower (p < 0.001) than that observed in
the absence of any inhibitor, which is 52.11(±2.16)%. A 23.91(±1.74)% value of decreased fluorescence
was obtained in the presence of bafilomycin, which reports approximately on the fraction degradable
via the UPS (Figure 5B), a value again significantly lower (p < 0.001) than that observed in the absence
of inhibitors. This result indicates that both UPS and ALP contribute to the clearance of exogenous
inserted TDP-43 aggregates. The same analysis was repeated using antibodies specific for only murine
TDP-43, confirming that all the TDP-43 detected in the cytoplasm was exogenous (human) and that
the levels of endogenous murine TDP-43 remained constant for the length of our time courses in the
presence of the inhibitors (Figure 5C). In the presence of epoxomicin or bafilomycin, the apparent rate
constants of clearance were found to be 7.84(±1.68) × 10−5 s−1 and 11.37(±1.94) × 10−5 s−1, respectively,
higher than that obtained in the absence of inhibitors, which is 4.78(±0.59) × 10−5 s−1 (p < 0.05 and
p < 0.001, respectively). This implies that when either the UPS or ALP is inhibited, the active clearance
system works more rapidly, albeit the extent of disposed aggregated TDP-43 is eventually lower.
As a negative control, we also monitored the levels of exogenous and endogenous TDP-43 in cells
pre-treated with epoxomicin or bafilomycin and transfected with control IBs (Figure 5B,C).
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Figure 5. TDP-43 levels in N2A cells following the treatment with UPS and ALP inhibitors and the
transfection with TDP-43 aggregates. (A) Representative confocal scanning microscope i ages of N2A
cells that were treated o not with 100 nM epoxomicin or 400 nM bafilomycin, then transfecte with
TDP-43 IBs and analyze t the indicat d time points after ransfection. Green fluorescence i dicates
total TDP-43 (human and muri e) detected with immunofluorescence. (B,C) Kinetic plots showing
cytoplasmic (B) and nuclear (C) TDP-43 derived fluorescence, detected with Abs, against the total
TDP-43 as a function of time after transfection of N2A cells with control IBs in the absence (yellow) or
in the presence of a pre-treatment with epoxomicin (magenta) or bafilomycin (pink) and TDP-43 IBs in
the absence (green) or in the presence of a pre-treatment with epoxomicin (blue) or bafilomycin (cyan).
The line in panel (B) represents the best fits to an exponential function. Error bars are S.D. §§ p < 0.01
relative to cells without inhibitors.
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3. Discussion
The decrease in the efficiency of the clearance systems in aging, as well as the presence of gene
mutations associated with cellular proteostasis in the familial forms of TDP-43 proteinopathies, suggests
that a failure of these protein degradation systems is a major factor in the aetiology of TDP-43 associated
disorders [39–41]. In this work we have transfected murine neuroblastoma N2A cells with human
TDP-43 aggregates and followed their ability to cause cell dysfunction along with the mechanism of their
clearance. Different methodologies were previously used to induce the accumulation of TDP-43 in the
cytoplasm, either by inducible gene expression or pre-formed aggregates transfection in different cell
models, such as human, SH-SY5Y and HEK293, or murine, NSC34 and N2a. Several techniques were
also used to analyze the TDP-43 species accumulating in the cytosol, such as immunohistochemistry
and FRAP [21,36]. Notably, the TDP-43 inclusions internalized in N2A neuroblastoma cells were found
to be ubiquitinated and phosphorylated at Ser409/410 residues, recapitulating the post-translational
modifications observed in neurodegenerative disorders [1,5,6,12].
The link between mitochondria and TDP-43 proteinopathies has been well established in patients
affected by both sporadic and familiar forms of these diseases [42]. Intracellular calcium shuttles
between the ER and mitochondria [43] and has been found to mediate apoptosis and other forms of
cell death [44]. In this study, the cytosolic TDP-43 inclusions were found to stimulate the release of
calcium from the mitochondrial stores, inducing ROS production and activating the apoptotic pathway,
thus causing a significant reduction of cell viability. TDP-43 was previously shown to colocalize with
mitochondrial markers in cellular and animal models of ALS and, thus, might alter the functions of
these organelles [45]. Since oxidative phosphorylation in the mitochondria is the major source of ROS,
oxidative stress may be linked to abnormalities in these organelles.
It has previously been established that both the UPS and ALP contribute to the clearance of cytosolic
TDP-43 in both cellular and animal models [19–21,36]. Our analysis has shown that, under conditions
in which TDP-43 aggregates are present, both the UPS and ALP contribute to their degradation and
that a pool of TDP-43 inclusions cannot be degraded, confirming previous findings [21,36]. Among the
three TDP-43 aggregates distinguishable here on the basis of their susceptibility to the various forms of
protein degradation, the un-disposable fraction corresponds to ca. 49%, whereas those degradable via
UPS and ALP account for ca. 24% and 26%, respectively, indicating that both routes contribute equally
to degradation of pre-formed TDP-43 assemblies. However, the UPS- and ALP-mediated degradation
processes appear to be kinetically independent, acting on different populations of TDP-43 aggregates
that are not in equilibrium or that interconvert on a slow time scale. Indeed, the inhibition of one system
would cause a deceleration of the degradation process and would result in similar levels of degraded
TDP-43, if the two populations were at equilibrium. By contrast, the rate constant of degradation is
significantly higher and the amount of degraded TDP-43 is lower when either UPS or ALP is inhibited
relative to the condition in which both routes are at work. This finding confirms previous observations
that the inhibition of one clearance pathway renders the remaining one more effective [46,47] and
reinforces the view that a cross-talk exists between the two clearance systems. These findings are
in agreement with our recent results obtained in NSC34 motor neurons [36], confirming a common
molecular mechanism in different cell types endowed with different UPS and ALP equipment. Our
evidence also suggests the importance of extending the analysis to future in vivo murine models in
order to test selective modulators of the UPS and ALP routes as effective drugs for the therapy of
neurodegenerative diseases with TDP-43 proteinopathies.
4. Materials and Methods
4.1. Purification of TDP-43 Inclusions and Internalization in N2a Neuroblastoma Cells
The gene for human full-length TDP-43 (residues 1–414) was cloned downstream of the glutathione
S-transferase (GST) gene in the pGEX-2T plasmid. Cultures of E. coli XL1 Blue cells (Agilent Technologies,
Santa Clara, CA, USA) were transformed with the resulting plasmid. Inclusion bodies were purified
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from IPTG induced bacteria harboring the pGEX-2T/TDP-43 plasmid (TDP-43 IBs) and the only pGEX-2T
plasmid (control IBs) by detergent-based procedures, as previously described [14]. Authenticated
murine Neuro2a (N2a) neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cultured in minimum
essential medium eagle (MEM), supplemented with 10% FBS, 1 mM glutamine, and 1% antibiotics.
Cell cultures were maintained in a 5% CO2 humidified atmosphere at 37 ◦C and grown until
they reached 80% confluence for a maximum of 20 passages. The cells were tested negatively for
mycoplasma contaminations. Cells were plated in 6-well plates containing coverslips at 30,000 cells/well
density [13,48]. The day after, the cells were transfected for 2 h using 4 µL of the PULSin protein delivery
reagent (Polyplus-transfection, Illkirch, France), without IBs (vehicle), with control IBs (4 µg/mL final
concentration), or with TDP-43 IBs (5.7 µg/mL final concentration) in culture medium without FBS,
according to the manufacturer’s instructions. In all our analyses, we used concentrations of TDP-43
IBs that were 30% higher than control IBs so that the two sets of IBs differed only in the presence of
TDP-43 aggregates [14]. After transfection, the culture medium was replaced with fresh MEM with
10% FBS and the biological analyses were performed.
4.2. Confocal Microscopy Analysis of TDP-43 Inclusions in N2A Neuroblastoma Cells
The levels of TDP-43 were analyzed following the transfection of TDP-43 IBs or control IBs or
vehicle to N2A cells seeded on glass coverslips. After transfection, N2a cells were washed with
PBS, fixed in 2% (w/v) buffered paraformaldehyde for 10 min at room temperature (20 ◦C), and
permeabilized with a 0.5% (v/v) Triton X-100 solution for 5 min. Then the cells were incubated for
60 min at 37 ◦C with 1:500 mouse monoclonal anti-TDP-43 antibodies (Novus Biologicals, Littleton,
CO, USA) or with 1:500 rabbit polyclonal anti-murine TDP-43 antibodies (LSBio, Seattle, WA, USA),
that only recognize the murine endogenous protein, and then for 90 min with 1:1000 diluted Alexa
Fluor 488-conjugated anti-mouse or 594-conjugated anti-rabbit secondary antibodies, respectively, as
previously reported [21,36]. In a set of experiments, following the transfection with control IBs, the
cells were counterstained for 15 min with 5.0 µg/mL Alexa Fluor 488-conjugated wheat germ agglutinin
(Thermo Fisher Scientific, Waltham, MA, USA) and fixed in 2% (w/v) buffered paraformaldehyde
for 10 min at room temperature (20 ◦C). After plasma membrane permeabilization with a 0.5% (v/v)
Triton X-100 solution for 5 min, the coverslips were incubated for 60 min with 1:500 rabbit polyclonal
anti-murine TDP-43 antibodies (LSBio, Seattle, WA, USA) and then for 90 min with 1:1000 diluted
Alexa Fluor 594-conjugated anti-rabbit antibodies. Cells were analyzed after double excitation at 488
and 594 nm using a Leica TCS SP5 confocal scanning microscope (Leica Microsystems, Mannheim,
Germany) equipped with an argon laser source and a Leica Plan Apo 63× oil immersion objective. A
series of optical sections (1024 × 1024 pixels), 1.0 µm in thickness, was taken through the cell depth
for each examined sample. Between 50–60 cells were analyzed on regions of interest (ROI) for each
examined sample, in three different experiments, using the ImageJ software (NIH, Bethesda, MD, USA).
Cytosolic TDP-43 levels (green) were assessed by selecting multiple ROIs per cell in the cytoplasmic
compartment, excluding the nucleus area, following background subtraction. Similarly, nuclear
TDP-43 levels (red) were measured by selecting one–two ROIs per cell in the nuclear compartment,
excluding the cytoplasmic area, following the background subtraction. The fluorescence intensities
were expressed as percentages of cells analyzed immediately after the 2 h transfection phase (time 0 h),
taken as 100%.
4.3. Analysis of Phosphorylation and Ubiquitination of TDP-43 IBs
The analysis of phosphorylation and ubiquitination of TDP-43 was carried out following the
transfection of TDP-43 IBs or control IBs to N2A cells seeded on glass coverslips (30,000 cells/well
density). After washing with PBS, cells were fixed in 2% (w/v) buffered paraformaldehyde for 10 min
at room temperature (20 ◦C) and permeabilized with a 0.5% (v/v) Triton X-100 solution for 5 min. The
co-localization of TDP-43 or phosphorylated TDP-43 with ubiquitin was monitored using 1:350 rabbit
polyclonal anti-TDP-43 antibody (Sigma-Aldrich, St. Louis, MO, USA) or 1:500 rabbit anti-TDP-43
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phosphorylation sites 409/410 (Cosmo Bio Co., Ltd., Tokyo, Japan) for 60 min at 37 ◦C, 1:150 mouse
monoclonal anti-ubiquitin antibodies (Thermo Fisher Scientific) for 60 min at 37 ◦C, and then with
1:1000 Alexa Fluor 488- and 594-conjugated secondary antibodies (Thermo Fisher Scientific) for 60 min
at 37 ◦C, as previously described [13]. The co-localization of TDP-43 with ubiquitin was estimated for
the regions of interest (50–60 cells) in three different experiments using the ImageJ (NIH, Bethesda,
MD, USA) and JACOP plugin software (Rasband, 1997–2008, rsb.info.nih.gov).
4.4. Analysis of Ca2+ Levels
The cytosolic levels of free Ca2+ were measured following the transfection of TDP-43 or control
inclusions to N2A cells seeded on glass coverslips and loaded with 4.0 µM Fluo4-AM (Thermo
Fisher Scientific), as previously described [49]. In a set of experiments, cells were pre-treated
for 60 min with 5.0 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), a competitive antagonist
of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA-R) [49,50], with 5 µM
CGP-37157 (CGP) (Sigma-Aldrich, St. Louis, MO, USA), an inhibitor of the mitochondrial Na+/Ca2+
exchanger [51], or with cyclosporine A (CsA) (Sigma-Aldrich), an inhibitor of the mitochondrial
permeability transition pore (mPTP) [52], or with culture medium without Ca2+. Fluorescence emission
was detected after excitation at 488 nm by using the confocal microscope described above. To quantify
the fluorescent signal intensities, 80–100 cells were analyzed using ImageJ software (NIH, Bethesda,
MD, USA) and the fluorescence intensities were expressed as percentages of cells treated with vehicle,
taken as 100%.
4.5. Measurement of Intracellular ROS Production, Caspase-3 Activation and Cell Viability
Intracellular ROS production and caspase-3 activity were analyzed following the transfection of
TDP-43 or control inclusions to N2A cells seeded on glass coverslips and loaded with CM-H2DCFDA
and using FAMFLICA™ Caspases 3&7 solution (Caspase 3&7 FLICA kit FAM-DEVDFMK,
Immunochemistry Technologies, LLC, Bloomington, MN, USA), as previously reported [13,14].
Fluorescence emission was detected after excitation at 488 nm by using the confocal microscopy
described above. To quantify the fluorescent signal intensities, 80–100 cells were analyzed using ImageJ
software (NIH, Bethesda, MD, USA), and the fluorescence intensities were expressed as percentages of
cells treated with vehicle, taken as 100%.
The cytotoxicity of TDP-43 inclusions was assessed on N2A cells seeded in
96-well plates, 24 h following the transfection of TDP-43 IBs or control IBs, by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as previously described [13].
Cell viability was expressed as the percentage of MTT reduction relative to cells that were treated with
vehicle, taken as 100%.
4.6. Time-Course of TDP-43 Degradation in the Absence or Presence of UPS and ALP Inhibitors
TDP-43 degradation was analyzed in N2a cells plated in 6-well plates (30,000 cells/well density) at
0 min, 30 min, 1 h, 2 h, 3 h, 15 h, and 24 h after transfection. In a set of experiments, the cells were
pre-treated with 100 nM epoxomicin (Abcam, Cambridge, UK), a potent proteasome inhibitor [53],
or with 400 nM bafilomycin (Abcam, Cambridge, UK), which inhibits autophagic flux by preventing
the acidification of endosomes and lysosomes [54]. Then, the cells were washed with PBS, fixed in
2% (w/v) buffered paraformaldehyde for 10 min at room temperature (20 ◦C), and permeabilized
with a 0.5% (v/v) Triton X-100 solution for 5 min. Then, the cells were incubated for 60 min at
37 ◦C with 1:500 mouse monoclonal anti-TDP-43 antibodies (Novus Biologicals, Littleton, CO, USA)
or with 1:500 rabbit polyclonal anti-murine TDP-43 antibodies (LSBio, Seattle, WA, USA), which
only recognize the murine protein, and for 90 min with 1:1000 diluted Alexa Fluor 488-conjugated
anti-mouse or 594-conjugated anti-rabbit secondary antibodies, respectively, and then analyzed by
confocal microscopy, as described above.
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4.7. Statistical Analysis
Data were expressed as means ± standard deviation (S.D.). Comparisons between different groups
were performed using one-way ANOVA followed by Bonferroni’s post-comparison test. A p-value
lower than 0.05 was considered statistically significant.
5. Conclusion
In summary, these findings identify the mitochondria as the main responsible organelle for
the early neuronal dysfunction induced by TDP-43 aggregates. Moreover, our evidences indicate a
cross-talk between the UPS and ALP clearance systems, which appear to be unable to completely
degrade the TDP-43 inclusions in neurodegenerative diseases.
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ALP autophagy-lysosomal pathway
ALS Amyotrophic lateral sclerosis
CGP CGP-37157
CNQX 6-cyano-7-nitroquinoxaline-2,3-dione
CsA cyclosporine A
DMEM Dulbecco’s Modified Eagle’s Medium
FBS fetal bovine serum
FTLD frontotemporal lobar degeneration
GST glutathione S-transferase
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TDP-43 TAR DNA-binding protein 43
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References
1. Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; Schuck, T.;
Grossman, M.; Clark, C.M.; et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Science 2006, 314, 130–133. [CrossRef] [PubMed]
2. Igaz, L.M.; Kwong, L.K.; Xu, Y.; Truax, A.C.; Uryu, K.; Neumann, M.; Clark, C.M.; Elman, L.B.; Miller, B.L.;
Grossman, M.; et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic
inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Am. J. Pathol. 2008, 173, 182–194. [CrossRef] [PubMed]
3. Rowland, L.P.; Shneider, N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2011, 344, 1688–1700. [CrossRef]
[PubMed]
4. Ling, S.C.; Polymenidou, M.; Cleveland, D.W. Converging mechanisms in ALS and FTD: Disrupted RNA
and protein homeostasis. Neuron 2013, 79, 416–438. [CrossRef] [PubMed]
5. Davidson, Y.; Kelley, T.; MacKenzie, I.R.A.; Pickering-Brown, S.; Du Plessis, D.; Neary, D.; Snowden, J.S.;
Mann, D.M.A. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR
DNA-binding protein, TDP-43. Acta Neuropathol. 2007, 113, 521–533. [CrossRef]
6. Arai, T.; Hasegawa, M.; Akiyama, H.; Ikeda, K.; Nonaka, T.; Mori, H.; Mann, D.; Tsuchiya, K.; Yoshida, M.;
Hashizume, Y.; et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal
lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351, 602–611.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 3685 12 of 14
7. Ferraiuolo, L.; Kirby, J.; Grierson, A.J.; Sendtner, M.; Shaw, P.J. Molecular pathways of motor neuron injury in
amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 7, 616–630. [CrossRef]
8. Borroni, B.; Alberici, A.; Buratti, E. Review: Molecular pathology of frontotemporal lobar degenerations.
Neuropathol. Appl. Neurobiol. 2019, 45, 41–57. [CrossRef]
9. Lee, E.B.; Lee, V.M.Y.; Trojanowski, J.Q. Gains or losses: Molecular mechanisms of TDP43-mediated
neurodegeneration. Nat. Rev. Neurosci. 2011, 13, 38–50. [CrossRef]
10. Cascella, R.; Capitini, C.; Fani, G.; Dobson, C.M.; Cecchi, C.; Chiti, F. Quantification of the relative
contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43)
proteinopathies. J. Biol. Chem. 2016, 291, 19437–19448. [CrossRef]
11. Capitini, C.; Conti, S.; Perni, M.; Guidi, F.; Cascella, R.; De Poli, A.; Penco, A.; Relini, A.; Cecchi, C.; Chiti, F.
TDP-43 Inclusion Bodies Formed in Bacteria Are Structurally Amorphous, Non-Amyloid and Inherently
Toxic to Neuroblastoma Cells. PLoS ONE 2014, 9, e86720. [CrossRef] [PubMed]
12. Ayala, Y.M.; Zago, P.; D’Ambrogio, A.; Xu, Y.F.; Petrucelli, L.; Buratti, E.; Baralle, F.E. Structural determinants
of the cellular localization and shuttling of TDP-43. J. Cell Sci. 2008, 121, 3778–3785. [CrossRef] [PubMed]
13. Winton, M.J.; Igaz, L.M.; Wong, M.M.; Kwong, L.K.; Trojanowski, J.Q.; Lee, V.M.Y. Disturbance of Nuclear
and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration,
and Aggregate Formation. J. Biol. Chem. 2008, 283, 13302–13309. [CrossRef] [PubMed]
14. Chou, C.C.; Zhang, Y.; Umoh, M.E.; Vaughan, S.W.; Lorenzini, I.; Liu, F.; Sayegh, M.; Donlin-Asp, P.G.;
Chen, Y.H.; Duong, D.M.; et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic
transport in ALS/FTD. Nat. Neurosci. 2018, 21, 228–239. [CrossRef] [PubMed]
15. Grosskreutz, J.; Bosch, L.V.D.; Keller, B.U. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium
2010, 47, 165–174. [CrossRef] [PubMed]
16. Lautenschläger, J.; Prell, T.; Ruhmer, J.; Weidemann, L.; Witte, O.W.; Grosskreutz, J. Overexpression of
human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse
embryonic motor neurons. Exp. Neurol. 2013, 247, 91–100. [CrossRef] [PubMed]
17. Krols, M.; van Isterdael, G.; Asselbergh, B.; Kremer, A.; Lippens, S.; Timmerman, V.; Janssens, S.
Mitochondria-associated membranes as hubs for neurodegeneration. Acta Neuropathol. 2016, 131, 505–523.
[CrossRef]
18. Berson, A.; Sartoris, A.; Nativio, R.; Van Deerlin, V.; Toledo, J.B.; Porta, S.; Liu, S.; Chung, C.Y.; Garcia, B.A.;
Lee, V.M.Y.; et al. TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. Curr. Biol.
2017, 27, 3579–3590. [CrossRef]
19. Urushitani, M.; Sato, T.; Bamba, H.; Hisa, Y.; Tooyama, I. Synergistic effect between proteasome and
autophagosome in the clearance of polyubiquitinated TDP-43. J. Neurosci. Res. 2010, 88, 784–797. [CrossRef]
20. Crippa, V.; Sau, D.; Rusmini, P.; Boncoraglio, A.; Onesto, E.; Bolzoni, E.; Galbiati, M.; Fontana, E.; Marino, M.;
Carra, S.; et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins
involved in amyotrophic lateral sclerosis (ALS). Hum. Mol. Genet. 2010, 19, 3440–3456. [CrossRef]
21. Scotter, E.L.; Vance, C.; Nishimura, A.L.; Lee, Y.B.; Chen, H.J.; Urwin, H.; Sardone, V.; Mitchell, J.C.; Rogelj, B.;
Rubinsztein, D.C.; et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance
of soluble and aggregated TDP-43 species. J. Cell Sci. 2014, 127, 1263–1278. [CrossRef] [PubMed]
22. Barmada, S.J.; Serio, A.; Arjun, A.; Bilican, B.; Daub, A.; Ando, D.M.; Tsvetkov, A.; Pleiss, M.; Li, X.; Peisach, D.;
et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Methods
2014, 10, 677–685. [CrossRef] [PubMed]
23. Ju, J.S.; Fuentealba, R.A.; Jackson, E.; Piwnica-Worms, D.; Baloh, H.; Wehil, C.C. Valosin-containing protein
(VCP) is required for autophagy and is disrupted in VCP disease. J. Cell Biol. 2009, 187, 875–888. [CrossRef]
24. Johnson, J.O.; Mandrioli, J.; Banatar, M.; Abramzon, Y.; Van Deerlin, V.M.; Trojanowski, J.Q.; Gibbs, J.R.;
Brunetti, M.; Gronka, S.; Wuu, J.; et al. Exome sequencing reveals VCP mutations as a cause of familial ALS.
Neuron 2010, 68, 857–864. [CrossRef] [PubMed]
25. Parkinson, N.; Ince, P.G.; Smith, M.O.; Highley, R.; Skibinski, G.; Andersen, P.M.; Morrison, K.E.; Pall, H.S.;
Hardiman, O.; Collinge, J.; et al. MRC Proteomics in ALS Study, FReJA Consortium. ALS phenotypes with
mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006, 67, 1074–1077. [CrossRef]
26. Maruyama, H.; Morino, H.; Ito, H.; Izumi, Y.; Kato, H.; Watanabe, Y.; Kinoshita, Y.; Kamada, M.; Nodera, H.;
Suzuki, H.; et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465, 223–226.
[CrossRef]
Int. J. Mol. Sci. 2019, 20, 3685 13 of 14
27. Pottier, C.; Bieniek, K.F.; Finch, N.; van de Vorst, M.; Baker, M.; Perkersen, R.; Brown, P.; Ravenscroft, T.; van
Blitterswijk, M.; Nicholson, A.M.; et al. Whole-genome sequencing reveals important role for TBK1 and
OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol.
2015, 130, 77–92. [CrossRef]
28. Fecto, F.; Yan, J.; Vemula, S.P.; Liu, E.; Yang, Y.; Chen, W.; Zheng, J.G.; Shi, Y.; Siddique, N.; Arrat, H.;
et al. SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Arch. Neurol. 2011, 68,
1440–1446. [CrossRef]
29. Rea, S.L.; Majcher, V.; Searle, M.S.; Layfield, R. SQSTM1 mutations–bridging Paget disease of bone and
ALS/FTLD. Exp. Cell Res. 2014, 325, 27–37. [CrossRef]
30. Cirulli, E.T.; Lasseigne, B.N.; Petrovski, S.; Sapp, P.C.; Dion, P.A.; Leblond, C.S.; Couthouis, J.; Lu, Y.-F.;
Wang, Q.; Krueger, B.J.; et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and
pathways. Science 2015, 347, 1436–1441. [CrossRef]
31. Freischmidt, A.; Wieland, T.; Richter, B.; Ruf, W.; Schaeffer, V.; Müller, K.; Marroquin, N.; Nordin, F.;
Hübers, A.; Weydt, P.; et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia.
Nat. Neurosci. 2015, 18, 631–636. [CrossRef] [PubMed]
32. Chow, C.Y.; Landers, J.E.; Bergren, S.K.; Sapp, P.C.; Grant, A.E.; Jones, J.M.; Everett, L.; Lenk, G.M.;
McKenna-Yasek, D.M.; Weisman, L.S.; et al. Deleterious Variants of FIG4, a Phosphoinositide Phosphatase,
in Patients with ALS. Am. J. Hum. Genet. 2009, 84, 85–88. [CrossRef] [PubMed]
33. Yang, Y.; Hentati, A.; Deng, H.X.; Dabbagh, O.; Sasaki, T.; Hirano, M.; Hung, W.Y.; Ouahchi, K.; Yan, J.;
Azim, A.C.; et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains,
is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 2001, 29, 160–165. [CrossRef]
[PubMed]
34. Hadano, S.; Hand, C.K.; Osuga, H.; Yanagisawa, Y.; Otomo, A.; Devon, R.S.; Miyamoto, N.;
Showguchi-Miyata, J.; Okada, Y.; Singaraja, R.; et al. A gene encoding a putative GTPase regulator
is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001, 29, 166–173. [CrossRef] [PubMed]
35. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; Nicholson, A.M.;
Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC hexanucleotide repeat in noncoding region
of C9ORF72 causes chromosome9p-linked FTD and ALS. Neuron 2011, 72, 245–256. [CrossRef] [PubMed]
36. Cascella, R.; Fani, G.; Capitini, C.; Rusmini, P.; Poletti, A.; Cecchi, C.; Chiti, F. Quantitative assessment of
the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy.
FASEB J. 2017, 12, 5609–5624. [CrossRef] [PubMed]
37. Duffy, L.M.; Chapman, A.L.; Shaw, P.J.; Grierson, A.J. The role of mitochondriain the pathogenesis of
amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2011, 37, 336–352. [CrossRef] [PubMed]
38. Imamura, K.; Sahara, N.; Kanaan, N.M.; Tsukita, K.; Kondo, T.; Kutoku, Y.; Ohsawa, Y.; Sunada, Y.;
Kawakami, K.; Hotta, A.; et al. Calcium dysregulation contributes to neurodegeneration in FTLD patient
iPSC-derived neurons. Sci. Rep. 2016, 6, 34904. [CrossRef] [PubMed]
39. McKinnon, C.; Tabrizi, S.J. The Ubiquitin-Proteasome System in Neurodegeneration. Antioxid. Redox Signal.
2014, 21, 2302–2321. [CrossRef]
40. Martinez-Lopez, N.; Athonvarangkul, D.; Singh, R. Autophagy and aging. Adv. Exp. Med. Biol. 2015, 847,
73–87.
41. Ruegsegger, C.; Saxena, S. Proteostasis impairment in LS. Brain Res. 2016, 1648, 571–579. [CrossRef] [PubMed]
42. Cenini, G.; Lloret, A.; Cascella, R. Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial
Point of View. Oxidative Med. Cell. Longev. 2019, 2019, 1–18. [CrossRef] [PubMed]
43. Berridge, M.J. The endoplasmic reticulum: A multifunctional signaling organelle. Cell Calcium 2002, 32,
235–249. [CrossRef] [PubMed]
44. Pinton, P.; Giorgi, C.; Siviero, R.; Zecchini, E.; Rizzuto, R. Calcium and apoptosis: ER-mitochondria Ca2+
transfer in the control of apoptosis. Oncogene 2008, 27, 6407–6418. [CrossRef] [PubMed]
45. Magrane, J.; Cortez, C.; Gan, W.B.; Manfredi, G. Manfredi, Abnormal mitochondrial transport and morphology
are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 2014, 23,
1413–1424. [CrossRef] [PubMed]
46. Wang, X.J.; Yu, J.; Wong, S.H.; Cheng, A.S.; Chan, F.K.; Ng, S.S.; Cho, C.H.; Sung, J.J.; Wu, W.K. A novel
crosstalk between two major protein degradation systems: Regulation of proteasomal activity by autophagy.
Autophagy 2013, 9, 1500–1508. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 3685 14 of 14
47. Bang, Y.; Kang, B.Y.; Choi, H.J. Preconditioning stimulus of proteasome inhibitor enhances aggresome
formation and autophagy in differentiated SH-SY5Y cells. Neurosci. Lett. 2014, 566, 263–268. [CrossRef]
48. Cappelli, S.; Penco, A.; Mannini, B.; Wilson, M.R.; Buxbaum, J.N.; Dobson, C.M.; Chiti, F.; Cascella, R.;
Ecroyd, H.; Li, X.; et al. Effect of molecular chaperones on aberrant protein oligomers in vitro: Super-versus
sub-stoichiometric chaperone concentrations. Biol. Chem. 2016, 397, 401–415. [CrossRef]
49. Cascella, R.; Evangelisti, E.; Bigi, A.; Becatti, M.; Fiorillo, C.; Stefani, M.; Chiti, F.; Cecchi, C. Soluble Oligomers
Require a Ganglioside to Trigger Neuronal Calcium Overload. J. Alzheimers Dis. 2017, 60, 923–938. [CrossRef]
50. Evangelisti, E.; Cascella, R.; Becatti, M.; Marrazza, G.; Dobson, C.M.; Chiti, F.; Stefani, M.; Cecchi, C. Binding
affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein
misfolding diseases. Sci. Rep. 2016, 6, 32721. [CrossRef]
51. Cox, D.A.; Matlib, M.A. A role for the mitochondrial Na(+)-Ca2+ exchanger in the regulation of oxidative
phosphorylation in isolated heart mitochondria. J. Biol. Chem. 1993, 268, 938–947. [PubMed]
52. Fournier, N.; Ducet, G.; Crevat, A. Action of cyclosporine on mitochondrial calcium fluxes.
J. Bioenerg. Biomembr. 1987, 19, 297–303. [CrossRef] [PubMed]
53. Meng, L.; Mohan, R.; Kwok, B.H.B.; Elofsson, M.; Sin, N.; Crews, C.M. Epoxomicin, a potent and selective
proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 1999, 96,
10403–10408. [CrossRef] [PubMed]
54. Yamamoto, A.; Tagawa, Y.; Yoshimori, T.; Moriyama, Y.; Masaki, R.; Tashiro, Y. Bafilomycin A1 prevents
maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat
hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 1998, 23, 33–42. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
